PMID- 19004654
OWN - NLM
STAT- MEDLINE
DCOM- 20090810
LR  - 20181201
IS  - 1094-6950 (Print)
IS  - 1094-6950 (Linking)
VI  - 12
IP  - 1
DP  - 2009 Jan-Mar
TI  - Effects of short-term risedronate on bone resorption and patient satisfaction in 
      postmenopausal osteoporosis patients.
PG  - 77-83
LID - 10.1016/j.jocd.2008.09.001 [doi]
AB  - This multicenter, open-label study evaluated the effects of short-term 
      risedronate on bone resorption and patient satisfaction in postmenopausal women 
      with osteoporosis in Brazil. Entry requirements included: osteoporosis of the 
      spine/femoral neck diagnosed by a bone mineral density (BMD) T-score<or=-2.5 or 
      radiographic fragility fracture within the last year and no treatment with 
      osteoporosis medication in the preceding 3 mo. Patients were treated with once 
      weekly risedronate of 35 mg for 12 wk. Patients also received 1000 mg calcium 
      carbonate and 400 IU vitamin D. The main outcome was the effect on bone 
      resorption, as assessed by the quantification of serum C-telopeptide of type I 
      collagen (CTX). Of the 556 women screened, 480 women received >or=1 dose of study 
      drug (intent-to-treat [ITT] population), and 390 completed treatment (81%). After 
      12 wk, CTX decreased in 94% of patients (from 0.419+/-0.234 to 0.158+/-0.171 
      microg/L, p<0.0001). Mean CTX reduction was 60.6%. Patient satisfaction was 
      good/excellent in 91.7% of patients. A total of 156 adverse events (AEs) were 
      reported by 113 (23.5%) patients in the ITT population. Digestive symptoms 
      emerged or worsened in 7.1% and 3.5%, respectively. Five patients (1.0%) 
      experienced serious AEs, not considered to be related to risedronate. In 
      conclusion, risedronate significantly reduced serum CTX after 12-wk treatment. 
      Almost all patients reported good/excellent satisfaction.
FAU - Fernandes, Cesar E
AU  - Fernandes CE
AD  - Gynecology and Obstetric Department, Faculdade de Medicina do ABC, Santo Andre, 
      Sao Paulo, Brazil. cesarefernandes@uol.com.br
FAU - Zerbini, Cristiano
AU  - Zerbini C
FAU - Russo, Luis A
AU  - Russo LA
FAU - Albernaz, Marco A
AU  - Albernaz MA
FAU - Eis, Sergi R
AU  - Eis SR
FAU - Szejnfeld, Vera L
AU  - Szejnfeld VL
FAU - Pompei, Luciano M
AU  - Pompei LM
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20081111
PL  - United States
TA  - J Clin Densitom
JT  - Journal of clinical densitometry : the official journal of the International 
      Society for Clinical Densitometry
JID - 9808212
RN  - 0 (Biomarkers)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Collagen Type I)
RN  - 0 (Peptides)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Bone Density Conservation Agents/*administration & dosage
MH  - Bone Remodeling/*drug effects
MH  - Bone Resorption/*prevention & control
MH  - Collagen Type I/blood
MH  - Etidronic Acid/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/*prevention & control
MH  - Patient Satisfaction
MH  - Peptides/blood
MH  - Prospective Studies
MH  - Risedronic Acid
EDAT- 2008/11/14 09:00
MHDA- 2009/08/11 09:00
CRDT- 2008/11/14 09:00
PHST- 2007/12/12 00:00 [received]
PHST- 2008/09/10 00:00 [revised]
PHST- 2008/09/10 00:00 [accepted]
PHST- 2008/11/14 09:00 [pubmed]
PHST- 2009/08/11 09:00 [medline]
PHST- 2008/11/14 09:00 [entrez]
AID - S1094-6950(08)00442-3 [pii]
AID - 10.1016/j.jocd.2008.09.001 [doi]
PST - ppublish
SO  - J Clin Densitom. 2009 Jan-Mar;12(1):77-83. doi: 10.1016/j.jocd.2008.09.001. Epub 
      2008 Nov 11.